Promomed DM's long-term creditworthiness rating has been confirmed at giA-, with a stable outlook

28.11.2022

For investors

On November 24, 2022, the Expert RA rating agency confirmed the credit rating of Promomed DM LLC, a non-financial company, at the giA- level. The rating outlook is stable.


These indicators are due to the good financial results of the group since the last update. The agency's experts also assess the resilience to external shocks at an above–average level, Promomed Group's financial policy as balanced, and the debt burden level as comfortable.

"The Promomed strategy is aimed at solving two of the most important tasks for today – the creation of new highly effective domestic drugs for patients and the strengthening of the country's drug independence. Currently, the main focus is on expanding the product portfolio and scaling up production, which will allow us to maintain growth rates and ensure drug safety. The credit rating procedure is an objective analysis of the teamwork done for us, and the high assessment of experts is an excellent motivation for further progress," commented Maxim Smagin, CEO of Promomed Group.

The press release of the Expert RA rating agency is published on the website raexpert.ru .

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office